Phase 2 multi-crossover RCT in 55 patients with painful knee osteoarthritis: the oral CCR2/CCR5 antagonist CNTX-6970 gave no pain benefit vs placebo, with slightly higher pain on active drug; it was safe and relatively well tolerated.
RCTn = 55
Edwards et al. A double-blind, placebo-controlled, multi-crossover trial of treatment with a chemokine antagonist for knee osteoarthritis pain